FINWIRES · TerminalLIVE
FINWIRES

Toromont Industries公布的第一季度盈利和营收均超出预期;公司专注于电力和能源业务

By

-- 托罗蒙特工业公司(TIH.TO)周二晚间公布的第一季度财报显示,其盈利和营收均超出预期,同时该公司“将继续考虑投资其电力和能源业务增长的机会”。 截至2026年3月31日的第一季度,该公司净利润为9270万美元,即每股摊薄收益1.13美元,而去年同期为7444万美元,即每股摊薄收益0.91美元。该业绩高于FactSet汇总的每股1.07美元的普遍预期。 该季度营收增长至近12.3亿美元,而去年同期为10.9亿美元。该业绩也高于普遍预期的11.725亿美元。 “尽管全球贸易市场持续存在不确定性,但我们的团队在本季度表现出色,”总裁兼首席执行官迈克尔·S·麦克米兰表示,“营收和利润均有所增长,反映出公司大部分业务领域的良好执行。设备集团的新旧设备销售额均实现稳健增长,租赁和产品支持业务也表现良好。我们的AVL机柜业务持续增产,主要满足美国东部地区数据中心的需求。CIMCO的包装收入有所增长,但盈利能力有所下降,主要原因是项目进度安排和支持活动的延迟。订单量强劲,积压订单充足。我们的资产负债表和财务状况依然稳健,现金流充裕,营运资本管理良好。” 麦克米兰表示,基于运营业绩和市场需求,公司将继续考虑投资电力和能源业务增长的机会。 因此,自今日起,公司通过提前收购目前尚未持有的AVL股份的一半,将其持股比例提高至80%。公告指出,此次收购的股份由一位被动投资者持有,不会影响AVL总裁Vince DiCristofaro的持股情况或地位。此次股份收购价格为7100万美元,以现金支付,预计将在2026年第二季度计入约4500万美元的费用。 公司董事会还批准了每股0.56美元的季度股息,将于7月2日支付给截至6月5日营业结束时登记在册的股东。上月季度股息已上调7.7%至每股0.56美元。 周二,该公司股票在多伦多证券交易所收盘下跌1%,报208.86美元。

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS